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Structured Abstract  
Aims: Ectopic fat accumulation is related to insulin resistance and diabetes mellitus 
(DM). However, the effect of fatty liver on DM in non-obese individuals has not been 
clarified. We investigated whether liver fat accumulation assessed by computed 
tomography (CT) is associated with the incidence of DM. 
Methods: In a prospective population-based study, 640 Japanese men were followed up 
for 5 years. The liver to spleen (L/S) ratio of the CT attenuation value was used as the 
liver fat accumulation index. We calculated the odds ratio (OR) and 95% confidence 
interval (CI) for the DM incidence of per 1 standard deviation (SD) lower L/S and those 
of L/S <1.0 compared with L/S ≥1.0, using logistic regression models.  
Results: Both per 1 SD lower L/S and L/S <1.0 were significantly associated with a risk 
for DM incidence (1 SD lower L/S: OR=1.57, 95%CI=1.14–2.16; L/S <1.0: OR=2.27, 
95%CI=1.00–5.14). The relationship between L/S and incidence of DM was consistent 
in the obese and non-obese groups, with thresholds of BMI 25 kg/m2, waist 
circumference 85 cm, or visceral adipose tissue 100 cm2. 
Conclusions: Liver fat accumulation assessed by CT was associated with the incidence 
of DM. 
 
Keywords: Fatty liver; CT; Diabetes mellitus   
1. Introduction 
Ectopic fat accumulation is defined as the presence of lipid droplets within non-adipose 
tissues that do not normally contain much lipid. Many studies reported that ectopic fat 
accumulation leads to insulin resistance and causes diabetes mellitus [1-3]. Fatty liver, 
including non-alcoholic fatty liver disease (NAFLD) and alcohol-induced fatty liver, is 
a form of ectopic fat accumulation and is increasing globally [3].  
The Asian population is known to be more susceptible to both fatty liver and 
diabetes mellitus even with a normal body mass index (BMI) compared with the 
Western population [4, 5]. However, the clinical importance of fatty liver in non-obese 
individuals appears to be less recognized than that in the obese population, because 
population that develop diabetes mellitus tend to be obese. 
Epidemiologic studies demonstrated a relationship between fatty liver and the 
incidence of diabetes mellitus based on ultrasonography images [6-8]. Although 
ultrasonography is a well-established imaging technique for the screening of fatty liver, 
this method is restricted to qualitatively detecting the presence or absence of fatty liver. 
By contrast, computed tomography (CT) and magnetic resonance imaging can 
quantitatively measure mild to severe liver fat accumulation. The liver to spleen ratio 
(L/S ratio) using CT is correlated with the hepatic fat content and is used as an index for 
the assessment of fatty liver [9, 10]. However, to date, only a few prospective studies on 
liver fat accumulation assessed by CT and the incidence of diabetes mellitus have been 
reported [11, 12]. Currently, the relationship between the L/S ratio and the incidence of 
diabetes mellitus has not been clarified.  
Therefore, our study aimed to evaluate the association between liver fat 
accumulation as determined quantitatively using the L/S ratio and the risk for diabetes 
mellitus in a prospective cohort of general Japanese men in both an obese and a non-
obese group. 
 
2. Subjects, materials, and methods  
 
2.1 Study designs and participants 
 
A prospective population-based longitudinal study of Japanese men in Kusatsu City, 
Shiga, Japan was performed as the Shiga Epidemiological Study of Subclinical 
Atherosclerosis (SESSA) [13, 14]. Study participants were randomly selected from the 
Kusatsu City Basic Residents’ Register, aged 40–79 years at the baseline. In total, 1094 
men (participation rate 46.0%) agreed to participate in the SESSA. We performed a 
baseline survey from 2006 to 2008 and a follow-up survey from 2010 to 2014. Among 
the 853 men who participated in both the baseline and follow-up studies, we excluded 
those with diabetes at baseline (n=189), a lack of diabetes information at baseline (n=1), 
and missing variables (n=23; diabetes information at follow-up n=4, CT information 
n=3, adjustment variables for pack-year n=5, ethanol intake n=1, waist circumferences 
n=3, visceral adipose tissue (VAT) n=5, daily step count n=2). Finally, 640 participants 
were analyzed in the present study. This study followed the Declaration of Helsinki and 
was approved by the Institutional Review Board of Shiga University of Medical 
Science. Every participant provided written informed consent. 
 
2.2 Measurements   
 
We performed anthropometries, questionnaires, examinations, including blood 
sampling, CT scan, and further examinations, both at the baseline and follow-up 
surveys. 
  
2.2.1 Anthropometries and questionnaires 
 
We measured body weight and height. The BMI was calculated as weight (kg) divided 
by height squared (m²). The waist circumference was measured twice at the umbilicus 
level in a standing position at the end of the exhalation phase, and mean values were 
calculated. The office blood pressure was obtained from the mean of two consecutive 
measurements on a participant’s right arm in a seated position after a 5-minute rest 
using an automated sphygmomanometer (BP-880; Omron Health Care Co. Ltd, Tokyo, 
Japan). Step counts for 8 days consecutively were obtained using a pedometer (DIGI-
WALKER DW-200; Yamasa Tokei Keiki Co. Ltd, Tokyo, Japan). Because the step 
counts of the first day were recorded for only a half day, we calculated the mean of 
seven consecutive days from the second to the eighth day. We excluded any extreme 
counts; <100 or ≥50000 steps/day. 
Self-administered questionnaires were used to obtain demographic information, 
family history of diabetes mellitus, smoking status, alcohol drinking status, medication, 
medical history, and other lifestyle factors. Once the participants had completed the 
questionnaires, trained nurses confirmed the provided data. A family history of diabetes 
mellitus was defined as its diagnosis in the participant’s father and/or mother. Alcohol 
consumption was calculated as the daily ethanol intake (g/day) from self-reported 
questionnaires. The pack-year was calculated by multiplying the mean number of 
cigarette packs smoked daily by the number of years smoking.  
 
2.2.2 Blood sampling 
 
Blood samples were obtained after overnight fasting for a minimum of 12 hours. Plasma 
glucose levels were determined from NaF-treated plasma using a hexokinase glucose-6 
phosphate-dehydrogenase enzymatic assay, hemoglobin A1c (HbA1c) and insulin levels 
were determined using a latex agglutination immunoassay and an enzyme-linked 
immunosorbent assay, respectively (Kyowa Medix, Tokyo, Japan). Lipid measurements 
were standardized according to the protocol of the Centers for Disease Control and 
Prevention/Cholesterol Reference Method Laboratory Network [15]. Total cholesterol 
and triglycerides were measured using enzymatic assays, and high-density lipoprotein 
cholesterol was determined using a direct method. Aminotransferase and gamma-
glutamyl transferase were measured using the modified Japan Society of Clinical 
Chemistry reference method [16]. 
 
2.2.3 Assessment of diabetes mellitus 
 
The HbA1c level was converted from the method of the Japan Diabetes Society (JDS) 
to the method of the National Glycohemoglobin Standardization Program (NGSP) using 
the following formula: HbA1c (NGSP) (%) = 1.02 * HbA1c (JDS) (%) + 0.25 [17]. In 
the present study, for both the baseline and follow-up surveys, we diagnosed diabetes as 
having an HbA1c (NGSP) level of ≥6.5% and/or a fasting plasma glucose level of 
≥7 mmol/L, and/or any diabetes medication use. 
 
2.2.4 Assessment of liver fat accumulation and VAT by non-contrast CT 
 
We used the L/S ratio in non-contrast CT as the index of liver fat accumulation as 
previously described [18]. The hepatic and splenic Hounsfield unit (HU) attenuation 
values were measured at the T12–L1 disc space and at three regions of interest (ROI) 
for both the liver and the spleen. Each ROI was approximately 120 mm2. The L/S ratio 
was calculated by taking mean HU measurement of liver ROIs and dividing it by the 
mean HU measurements of spleen ROIs. The ROI for the liver was placed manually to 
avoid major vessels. We defined an L/S ratio <1.0 as prevalent fatty liver and an L/S 
ratio ≥1.0 as non-fatty liver individuals. This definition was applied because an L/S 
ratio <1.0, which is equivalent to liver attenuation <51 HU was reported as an indicator 
for any form (mild-moderate-sever) of fatty liver [19-22]. To estimate the VAT and 
subcutaneous adipose tissue areas, a single CT image of the L4–L5 vertebral space was 
selected [14, 18]. The inner and outer aspects of the abdominal walls were manually 
tracked, and the respective areas were calculated using image analysis software 
(SliceOmatic; Tomovision, Montreal, Canada).  
CT imaging was performed as previously described [4, 14]. Two types CT 
scanner were used during the examination period: a GE-Imatron C150 Electron Beam 
Tomography system (EBCT; GE Medical Systems, South San Francisco, CA; slice 
thickness, 6 mm) from May 2006 through to August 2007 and thereafter a 16-row multi 
detector row CT system (MDCT, Aquilion-16™; Toshiba Medical Systems, Tochigi, 
Japan; slice thickness, 7 mm). All CT images were analyzed at Shiga University of 
Medical Science by trained researchers who were blinded to the participants’ 
characteristics.  
 
2.3 Statistical analysis 
 
Characteristics of the participants are presented as the mean ± standard deviation (SD), 
median (interquartile range), or percentage. For the differences between the L/S ratio 
<1.0 and the L/S ratio ≥1.0, a t-test or Man-Whitney test was applied for continuous 
variables and a χ2 test was used for categorical variables. To calculate the odds ratio 
(OR) and 95% confidence interval (CI) for the incidence of diabetes mellitus in 5 years, 
logistic regression was used. We estimated the OR and 95% CI of the L/S ratio <1.0 
compared to the L/S ratio ≥1.0 and those of the per 1 SD lower in the L/S ratio whether 
the change in continuous variable would also have the effect on the incidence of 
diabetes mellitus. Adjusting covariates were as follows: Model 1, age (years) and CT 
type; Model 2, family history of diabetes, smoking (pack-year), ethanol intake (g/day), 
and exercise (step count/day) in addition to Model 1; Model 3, BMI (kg/m2) in addition 
to Model 2; Model 4, waist circumference (cm) in addition to Model 2; Model 5, VAT 
(cm2) in addition to Model 2. We investigated whether the impact of fatty liver on the 
incidence of diabetes mellitus was similar both in the obese and non-obese groups using 
stratified analysis. We assigned the data according to the obesity indices, whereby non-
obese was defined as BMI <25 kg/m2, waist circumference <85 cm, or VAT <100 cm2 
and obese as BMI ≥25 kg/m2, waist circumference ≥85 cm, or VAT ≥100 cm2 [23]. P-
values for the interaction between obesity category and L/S ratio were also determined. 
Statistical significance was defined as a two-tailed P-value <0.05. All statistical 




Baseline characteristics of the participants are presented in Table 1. The mean age was 
63.5 years, BMI 23.4 kg/m2, and waist circumference 85.1 cm. The mean (SD) value of 
the L/S ratio among all participants were 1.12 (0.18). The prevalence of an L/S ratio 
<1.0 was 18.9%. Among the 640 participants, 36 (5.6%) developed diabetes mellitus in 
4.93 ± 1.35 years follow-up. The L/S ratio <1.0 group compared with the L/S ratio ≥1.0 
group was significantly younger, had significantly higher fasting plasma glucose, 
HbA1c, triglycerides, liver enzymes, C-reactive protein (CRP), homeostasis model 
assessment of insulin resistance (HOMA-IR), and homeostasis model assessment of β, 
and had significantly lower high-density lipoprotein cholesterol. 
Table 2 presents the ORs and 95% CIs of diabetes mellitus incidence. An L/S 
ratio <1.0 was significantly associated with a higher risk for diabetes mellitus incidence 
(OR [95% CI]: Model 2; 2.78 [1.30–5.95]). This association remained even after taking 
obesity indices into consideration, although the relationship was slightly attenuated (OR 
[95% CI]: Model 5; 2.27 [1.00–5.14]). Similarly, per 1 SD (0.18) lower in L/S ratio was 
significantly associated with a higher risk for diabetes mellitus incidence even when 
adjusted for obesity parameters (OR [95% CI]: Model 2; 1.67 [1.24–2.25], Model 5; 
1.57 [1.14–2.16]). 
We performed a stratified analysis according to the obesity indices (Table 3). 
The relationship between the L/S ratio and incidence of diabetes mellitus was consistent 
across the subgroups of both the non-obese and obese groups. Per 1 SD lower in L/S 
ratio was partly significant with the risk for diabetes mellitus incidence in some 
stratified analysis, group of waist circumference ≥85 cm (OR [95% CI]: 1.50 [1.04–
2.16]) and group of VAT ≥100 cm2 (OR [95% CI]: 1.57 [1.11–2.21]). Although the ORs 
were higher in the obese group (BMI ≥25 kg/m2, waist circumference ≥85 cm, or VAT 
≥100 cm2) compared with non-obese group (BMI <25 kg/m2, waist circumference <85 
cm, or VAT <100cm2), the ORs in the non-obese group were >1.0 and all the p-values 
for the interaction were not significant (p ≥ 0.05) between the obese and non-obese 
groups. 
 
4. Discussion  
 
The present study indicated that the L/S ratio assessed by CT was associated with a 
higher risk for diabetes mellitus incidence during the 5 year follow-up. This association 
was attenuated in the obesity index added models, but a statistically significant 
association was still observed. Additionally, the association between the L/S ratio and 
diabetes mellitus were consistent in both the non-obese and obese groups. To the best of 
our knowledge, our study is the first to demonstrate a long-term association of the L/S 
ratio with diabetes mellitus. 
In the recent NAFLD/Nonalcoholic Steatohepatitis guideline in Europe and 
Japan, the L/S ratio is an established estimate for the assessment of liver fat 
accumulation [24-26]. A longitudinal relationship between liver fat accumulation 
assessed by CT and an increased risk for type 2 diabetes mellitus (T2DM) was reported 
from the Multi-Ethnic Study of Atherosclerosis, using the other variable from the L/S 
ratio [11]. The Framingham Heart Study also reported a longitudinal association 
between liver fat accumulation and increased risk for T2DM using the CT liver-
phantom ratio [12]. From Asia, one cohort study showed liver fat accumulation 
associated with T2DM incidence in addition to pancreatic fat accumulation [27].  
Our data showed that the L/S ratio was continuously associated with the 
incidence of diabetes mellitus. From our stratified analysis, the ORs among the obese 
group were slightly higher than those of the non-obese group (Table 3). All p-values for 
the interaction between each obesity category and the L/S ratio were not statistically 
significant. Our data suggested that a lower L/S ratio has an impact on the incidence of 
diabetes in not only the obese but also the non-obese group.  
The potential mechanism of fatty liver in T2DM development may originate 
from expanded and inflamed adipose tissue. Insulin resistance strongly associates with a 
fatty liver and plays a key role in its development. The accumulation of ectopic fat in 
the liver impairs the ability of insulin to suppress glucose production and of very low-
density lipoproteins, resulting in hyperglycemia and hypertriglyceridemia, respectively. 
Ectopic fat accumulation increases the generation of reactive oxygen species, fluxes of 
free fatty acid, inflammatory hepato-cytokines, including CRP, interleukin-6, and tumor 
necrosis factor-alpha, and coagulation-fibrinolytic factors, which increase both hepatic 
and systemic insulin resistance [28-30]. In our study, CRP in the L/S ratio <1.0 group 
was higher than in the L/S ratio ≥1.0 group, suggesting an interaction between ectopic 
fat accumulation and systemic inflammation at baseline (Table 1). Furthermore, the 
HOMA-IR in the L/S <1.0 group was also significantly higher than in the L/S ≥1.0 
group, suggesting hepatic insulin resistance in the L/S <1.0 group (Table 1). 
Hepatokines, including fetuin-A, fibroblast growth factor-21, and retinol binding 
protein-4, may contribute to insulin resistance, although we did not measure these [31].  
Fatty liver occurs not only in the obese, but also frequently in the non-obese 
population [2, 32, 33]. In Asian countries, 8–25% of all NAFLD patients were reported 
to be non-obese or lean subjects, with a BMI <25 kg/m² [34]. In an international 
comparison study, Japanese in Japan were reported to have a higher liver fat content and 
a significantly lower L/S ratio than non-Hispanic whites in the United States despite a 
lower mean BMI [18]. One possible explanation for the discrepancy between obese and 
NAFLD individuals in Asia is a genetic difference. Single nucleotide polymorphism of 
the patatin-like phospholipase domain-containing protein 3 (PNPLA3), PNPLA3 
rs738409, displays a strong association with hepatic steatosis [35-37]. PNPLA3 
rs738409 polymorphism is more frequent in Asians than Caucasians or Africans [38, 
39]. It was suggested that this polymorphism causes apolipoprotein B deficiency and 
decreases the liver lipid excretion, leading to the risk for fatty liver disease. In addition, 
PNPLA3 rs738409 polymorphism was also associated with the incidence of T2DM in 
Japanese in a genome-wide association study [40]. Therefore, PNPLA3 polymorphism 
might be one of the key pathophysiologic factors why the Asian population tends to 
display a greater incidence of both fatty liver and diabetes mellitus with a lower BMI. 
Assessment of the presence of a fatty liver appears to be important for the prediction of 
future diabetes mellitus, particularly in the Asian population. 
Our data suggested that the L/S ratio assessed by a CT scan may provide more 
precise information about the potential risk for developing diabetes mellitus. Compared 
with ultrasonography, a CT scan is able to evaluate the severity of fatty liver 
quantitatively, however, radiation exposure is detrimental for patients. Therefore, in 
clinical settings, for those who display risk factors for fatty liver, ultrasonographic 
measurement might be important to detect its impact on diabetes mellitus.  
Our study has some strengths. The study participants were randomly selected 
from the general Japanese population, including both non-alcohol drinkers and regular 
alcohol drinkers, whereas many previous clinical studies focused only on the prognosis 
of NAFLD [41]. Assessment methods of our population survey were standardized and 
carefully controlled. The current study also has several limitations. First, this was a 
prospective cohort study conducted in only Japanese men. Therefore, this study cannot 
be generalized to the other ethnicities or females. Additionally, we diagnosed the 
incidence of diabetes mellitus using one-point glucose and HbA1c assessment and self-
reported medication use. And the effect of self-selection bias might remain. Finally, we 
did not consider the medication class effect which relate to insulin secretion or 
sensitivity although some of the antihypertensive and lipid-lowering agents were 
reported to be related with the new onset of diabetes [42] or reduce the risk of it [43-45]. 
In conclusion, the L/S ratio, indicating liver fat accumulation as assessed by 
CT, was associated with a higher risk for diabetes mellitus during a 5-year follow-up in 
a Japanese community-based study. Our data implied that the assessment of liver fat 
accumulation is an important predictor for diabetes mellitus regardless of whether or 
not a subject is obese. Prevention and early detection of fatty liver might be important 
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Table 1 – Baseline characteristics of the participants (n=640; men aged 40–79 years, 2006–2008, SESSA, Japan). 
 Total (n=640) L/S ≥1.0 (n=519) L/S <1.0 (n=121) P-value * 
Age (year) 63.5±9.9 64.0±9.9 61.4±9.5 0.009 
BMI (kg/m²) 23.4±2.8 23.1±2.6 25.0±2.9 <0.001 
Waist circumference (cm) 85.1±7.7 84.1±7.4 89.2±7.7 <0.001 
Visceral adipose tissue (cm²) 116.0±53.6 107.8±48.9 151.2±58.5 <0.001 
Systolic blood pressure (mmHg) 134.5±18.4 134.5±18.6 134.2±17.8 0.877 
Diastolic blood pressure (mmHg) 79.5±11.0 79.2±10.8 80.8±11.6 0.151 











Total cholesterol (mmol/L) 5.4±0.8 5.4±0.8 5.5±0.9 0.065 
HDL cholesterol (mmol/L) 1.6±0.5 1.6±0.5 1.4±0.4 <0.001 
Triglycerides (mmol/L) 1.1 (0.9-1.6) 1.1 (0.8-1.5) 1.6 (1.1-2.1) <0.001 
GOT (AST) (IU/L) 24.0 (20.0-30.0) 23.0 (20.0-28.0) 29.0 (23.0-39.0) <0.001 
GPT (ALT) (IU/L) 21.0 (16.0-29.0) 20.0 (15.0-25.0) 32.0 (22.0-50.0) <0.001 
γ-GTP (IU/L) 36.0 (24.0-55.0) 32.0 (22.0-51.0) 50.0 (37.0-87.0) <0.001 
High sensitivity CRP (mg/mL) 0.4 (0.2-0.8) 0.37 (0.2-0.8) 0.54 (0.4-0.9) <0.001 
HOMA-IR 0.9 (0.7-1.4) 0.9 (0.6-1.2) 1.5 (1.0-2.0) <0.001 
HOMA-β (%) 47.1 (33.8-64.7) 43.6 (31.9-59.0) 61.3 (44.8-90.0) <0.001 
Step count (/day) 8508±3715 8632±3799 7979±3293 0.081 
Pack-year 22.8 (5.0-41.0) 22.0 (4.5-40.1) 26.0 (9.5-44.0) 0.153 
Ethanol intake (g/day) 14.0 (1.0-37.0) 14.0 (1.0-37.0) 14.0 (1.4-43.0) 0.806 
EBCT, n (%) 462 (72.2) 365 (70.3) 97 (80.2) 0.032 
 
Results are the mean ± standard deviation, n (%) or median (interquartile range).  
*: Comparison according to L/S using t test, Mann-Whitney U test, or χ2 test appropriately. 
n, number; BMI, body mass index; HDL, high-density lipoprotein; CRP, C-reactive protein; HOMA-IR, homeostasis model assessment 
of insulin resistance; SESSA, Shiga Epidemiological Study of Subclinical Atherosclerosis; EBCT, electron beam computed tomography. 
Table 2 – Odds ratio for diabetes mellitus incidence according to the L/S ratio <1.0 and the per 1 SD lower in L/S ratio in the SESSA 
(2006–2008). 
 
 Odds ratio (95% confidence interval)  
 L/S ratio ≥1.0 L/S ratio <1.0  Per 1 SD lower in L/S ratio 
N events/total 23/519 13/121  36/640 
Model 1 Ref 2.79 (1.34-5.82)  1.67 (1.26-2.21) 
Model 2 Ref 2.78 (1.30-5.95)  1.67 (1.24-2.25) 
Model 3 Ref 2.08 (0.94-4.63)  1.47 (1.07-2.03) 
Model 4 Ref 2.18 (0.99-4.83)  1.53 (1.11-2.11) 
Model 5 Ref 2.27 (1.00-5.14)  1.57 (1.14-2.16) 
 
1 SD difference for L/S was 0.18. 
N events/total = Incidence diabetes mellitus/Population at risk. 
Model 1: age + CT type 
Model 2: Model 1 + parent DM history, smoking (pack-year), ethanol intake (g/day), and exercise (steps/day) 
Model 3: Model 2 + BMI (kg/m2) 
Model 4: Model 2 + Waist (cm) 
Model 5: Model 2 +VAT (cm2) 
SD, standard deviation; SESSA, Shiga Epidemiological Study of Subclinical Atherosclerosis; CT, computed tomography; DM, diabetes 
mellitus, BMI, body mass index; Waist, waist circumference; VAT, visceral adipose tissue. 
  
Table 3 – Odds ratio for diabetes mellitus incidence according to the L/S ratio <1.0 and the per 1 SD lower in L/S ratio stratified by 
obesity indices in the SESSA (2006–2008). 
 
 
N events/ total  
Odds ratio (95% confidence interval) P for interaction  
 L/S ratio ≥1.0 L/S ratio <1.0 Per 1 SD lower in L/S ratio * P  † P  
BMI <25 15/465 Ref 1.83 (0.45-7.39) 1.40 (0.65-3.01) 0.42 0.49 
BMI ≥25 21/175 Ref 2.16 (0.76-6.10) 1.45 (0.99-2.13)   
Waist <85 11/314 Ref 1.54 (0.26-9.08) 1.12 (0.42-3.00) 0.85 0.34 
Waist ≥85 25/326 Ref 2.18 (0.84-5.68) 1.50 (1.04-2.16)   
VAT <100 10/261 Ref 5.04 (0.68-37.35) 1.02 (0.30-3.43) 0.65 0.36 
VAT ≥100 26/379 Ref 2.01 (0.78-5.17) 1.57 (1.11-2.21)   
 
1SD difference for L/S was 0.18. 
N events/total = Incidence diabetes mellitus/Population at risk. 
Adjusted for: age, CT type, parent diabetes mellitus history, smoking (pack-year), ethanol intake (g/day), exercise (steps/day), and 
obesity indices BMI (kg/m2), Waist (cm), or VAT (cm2). 
* P for interaction on obesity indices (BMI, waist circumference, VAT) and L/S ratio <1.0. 
† P for interaction on obesity indices (BMI, waist circumference, VAT) and per 1 SD lower in L/S ratio. 
SD, standard deviation; SESSA, Shiga Epidemiological Study of Subclinical Atherosclerosis; CT, computed tomography; BMI, body 
mass index; Waist, waist circumference; VAT, visceral adipose tissue. 
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